Curtis Andrew Lachowiez: Ivosidenib + Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

In this video, Curtis Andrew Lachowiez, MD, discusses interim results from a small study of patients with IDH1-mutated myeloid malignancies who were treated with ivosidenib plus venetoclax, with or without azacitidine.